Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 30;17(12):2008. doi: 10.3390/ijms17122008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(A) Kaplan—Meier analysis of baseline CTCs to predict overall survival time in patients with mCRPC. The overall survival time was significantly shorter in patients with ≥5 CTCs. A total of 23 patients (38.3%) with <5 CTCs/7.5 mL of blood (group 1) had a median overall survival time of 20.0 months compared with 11.5 months in 37 patients (61.7%) with ≥5 CTCs (group 2) (p = 0.0017, log-rank test) and (B) Kaplan—Meier analysis of baseline CTC-EGFR to predict overall survival time in patients with mCRPC. The overall survival time was significantly shorter in patients with EGFR-positive CTCs. There were 45 (75.0%) with EGFR-negative CTCs (group 1) that had a median overall survival time of 20.0 months compared with 5.5 months in 15 patients (25.0%) with EGFR-positive CTCs (group 2) (p < 0.001, log-rank test).